Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer

Enzalutamide is a second-generation anti-androgen for treatment of castration-resistant prostate cancer (CPRC). It prolongs survival of CRPC patients, but its overall survival benefit is relatively modest (4.8 months) and by 24 months most patients progress on enzalutamide. To date, however, the mol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zhao, Jingwen, Zhao, Yu, Wang, Liguo, Zhang, Jun, Karnes, R. Jeffrey, Kohli, Manish, Wang, Guixia, Huang, Haojie
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5122410/
https://ncbi.nlm.nih.gov/pubmed/27221037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9535
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados